CClinicalTrials.gg
WithdrawnNCT03666429Updated Dec 3, 2020

Effectiveness of the NoseFrida Compared With Bulb Suction at Relieving Objective Signs of Nasal Obstruction and Reducing Return Visits in Pediatric Patients Presenting to the Emergency Department

An interventional study of Bulb suction and NoseFrida in Upper Respiratory Tract Infections, Nasal Suction and Return Emergency Department Visits, sponsored by Vanderbilt University Medical Center. Withdrawn at 1 site in United States. Open to participants aged 1 Day to 24 Months. Per ClinicalTrials.gov, last updated 2020-12-03.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

Why this study was withdrawn
PI left institution
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
1 Day to 24 Months
Sex
All
01

Study summary

The mainstay of treatment in viral upper and lower respiratory tract disease is airway clearance. Viral respiratory tract infections account for a substantial amount of emergency department (ED) visits, financial and stress burden on caregivers. In addition, they also account for a large number of ED return visits. While airway clearance is considered a mainstay of treatment the pragmatic effectiveness of various devices remain unstudied in patients who are discharged from the ED.

The objectives of this study are to compare the pragmatic effectiveness of two commonly used suction devices the NoseFrida and bulb suction and to provide a descriptive analysis on 72 hour return to ED rates and readmission rates. Patients will be enrolled October 15, 2018 to October 15, 2019 or until NoseFrida supplies are depleted. Fridababy will supply 500 NoseFrida devices and replacement filters. Patients aged 1 day to 24 months presenting Vanderbilt Childrens ED with symptoms of nasal congestion or bronchiolitis who require suctioning and will be discharged from the ED will be approached for enrollment. Exclusion criteria include no upper airway abnormalities or previously enrolled in study. The study design is a prospective and retrospective observational study. We anticipate about 500 patients to be enrolled in this study. Families will then be approached for consent to participate. Caregiver will fill out a data collection form then be instructed on how to use the NoseFrida. Next, family with trial it on their child while in the ED. Caregivers will then fill out a 7 point Likert survey on both the bulb suction and NoseFrida device. The family will go home with this device and a set of replacement filters and instructed to suction their child as needed. The primary investigator (PI) will then complete a 72 hour chart review to determine the number of return to ED visits and readmission rates. To compare ED returns with retrospective data, KSP will conduct a review of the business objects database using ICD9 codes specific for viral respiratory tract infections over the past 3 years to determine a control return ED visit rate. Data will be compared using a paired T-test. If data is not normally distributed we will use a Wilcoxon signed-rank test. We will also use a multivariable logistic model to examine associations adjusted for age and illness severity.

Read the detailed description

Background The mainstay of treatment in viral upper and lower respiratory tract disease is airway clearance. Viral respiratory tract infections account for a substantial amount of emergency department (ED) visits, financial and stress burden on caregivers. In addition, they also account for a large number of ED return visits. While airway clearance is considered a mainstay of treatment the pragmatic effectiveness of various devices remain unstudied in patients who are discharged from the ED.

Hypothesis:

There is no difference between the NoseFrida and the bulb suction at relieving objective signs of nasal obstruction or return ED visits.

Study Objective:

  1. To compare the use of the NoseFrida device with a retrospective control (bulb suction) to determine if there is a decrease in the number of ED return visits.
  2. To provide evidence based recommendations on the pragmatic effectiveness of two commonly used suction devices.
  3. To provide a descriptive analysis on 72 hour return to ED rates and readmission rates.

Methods:

The study design is a prospective and retrospective observational study. We anticipate about 500 patients to be enrolled in this study. Patients who present to Vanderbilt Childrens Emergency Department will be identified by key study personnel (KSP) based on inclusion and exclusion criteria. Families will then be approached for consent to participate. Caregiver will fill out a data collection form then be instructed on how to use the NoseFrida. Next, family with trial it on their child while in the ED. Caregivers will then fill out a 7 point Likert survey on both the bulb suction and NoseFrida device. The family will go home with this device and a set of replacement filters and instructed to suction their child as needed. The primary investigator (PI) will then complete a 72 hour chart review to determine the number of return to ED visits and readmission rates. The family will keep the suction device at the completion of the study. To compare ED returns with retrospective data, KSP will conduct a review of the business objects database using ICD9 codes specific for viral respiratory tract infections over the past 3 years to determine a control return ED visit rate. Data will be compared using a paired T-test. If data is not normally distributed we will use a Wilcoxon signed-rank test. We will also use a multivariable logistic model to examine associations adjusted for age and illness severity. Fridababy will provide supplies needed for the study, however the company will not have access to the raw data or PHI. Once the results are published in a scientific journal, then Fridababy will have access to the results.

02

Conditions studied

  • Upper Respiratory Tract Infections
  • Nasal Suction
  • Return Emergency Department Visits
03

In context

Respiratory Tract Infections

1,031 studies on the registry are indexed under Respiratory Tract Infections; 144 are open to participants now.

Browse Respiratory Tract Infections studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 1 day-24 months presenting to the ED with a complaint of nasal congestion or symptoms of bronchiolitis who require suctioning.
  2. Parent/guardian has used a bulb suction device in the past.
  3. This is the first presentation to Vanderbilt Childrens Emergency Department for current illness.
  4. Patient will be discharged from the emergency room.
  5. Parent/Guardian is able to read English.

Exclusion criteria

Exclusion Criteria:

  1. No upper airway abnormalities, i.e. cleft palate or choanal atresia.
  2. Previously enrolled in study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Bulb suction

    Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.

    Device: Bulb suction

  • Experimental
    NoseFrida

    Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.

    Device: NoseFrida

Interventions

  • DeviceBulb suction

    Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.

  • DeviceNoseFrida

    Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.

06

What researchers measure

Primary outcomes

  1. Parental satisfaction

    Measured on a 7 point Likert scale from 1 to 7 with 7 being strongly agree

    Time frame: at baseline

07

Study locations

1 site
  • Vanderbilt Childrens Emergency Department
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03666429
Lead sponsor
Vanderbilt University Medical Center
Collaborators
Fridababy
Responsible party
Sponsor
First posted
Sep 11, 2018
Start date
Jan 1, 2020 (estimated)
Primary completion
Nov 2020 (estimated)
Completion
Nov 2020 (estimated)
Last update
Dec 3, 2020

Study contacts

Donald Arnold, M.D.
study chair · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion